• Je něco špatně v tomto záznamu ?

Influence of clinical presentation, site, and extent of venous thrombosis on decision about duration of anticoagulation: Data from the international, prospective, observational WHITE study

G. Palareti, AA. Bignamini, T. Urbanek, M. Cini, YJ. Li, J. Madaric, K. Bouslama, GY. Sokurenko, GM. Andreozzi, J. Matuška, A. Mansilha, V. Barinov, WHITE study group

. 2022 ; 211 (-) : 140-146. [pub] 20220204

Jazyk angličtina Země Spojené státy americké

Typ dokumentu časopisecké články, pozorovací studie

Perzistentní odkaz   https://www.medvik.cz/link/bmc22019339

BACKGROUND: Low attention has generally been dedicated to the influence of clinical presentation, extent of venous thrombosis and presence of residual vein obstruction (RVO) on the decision about the duration of secondary prophylaxis after a first venous thromboembolism (VTE). AIM: This study aimed at investigating the role of the mentioned VTE characteristics on the therapeutic decision using the information collected in the international, prospective, observational WHITE study. RESULTS: 1240 patients were recruited by 79 clinical centers in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia). 35 patients had as index event a pulmonary embolism (PE) without a deep vein thrombosis (DVT), and all continued anticoagulation. We focused on the 1205 subjects with DVT. The treatment decision differed among countries; altogether, more than 85% of patients with proximal (with or without distal) DVT continued a prophylactic treatment with anticoagulants, or antithrombotics; 34% of patients with isolated distal DVT stopped treatment, and more than 85% of patients with a PE associated to a DVT continued treatment. At multivariable analysis, the presence of proximal DVT, signs of post-thrombotic syndrome (PTS), residual vein obstruction (RVO), maintenance <180 days and concomitant diseases was associated with increased probability to continue secondary prophylaxis. CONCLUSION: The presentation as proximal DVT (with or without PE) or isolated PE influenced the treating physicians' decision in favor of extension of secondary prophylaxis, together with the presence of concomitant diseases and local conditions which may increase the risk of post-thrombotic syndrome.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22019339
003      
CZ-PrNML
005      
20220804135557.0
007      
ta
008      
220720s2022 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.thromres.2022.01.025 $2 doi
035    __
$a (PubMed)35151009
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Palareti, Gualtiero $u Arianna Anticoagulazione Foundation, Bologna, Italy. Electronic address: Gualtiero.palareti@unibo.it
245    10
$a Influence of clinical presentation, site, and extent of venous thrombosis on decision about duration of anticoagulation: Data from the international, prospective, observational WHITE study / $c G. Palareti, AA. Bignamini, T. Urbanek, M. Cini, YJ. Li, J. Madaric, K. Bouslama, GY. Sokurenko, GM. Andreozzi, J. Matuška, A. Mansilha, V. Barinov, WHITE study group
520    9_
$a BACKGROUND: Low attention has generally been dedicated to the influence of clinical presentation, extent of venous thrombosis and presence of residual vein obstruction (RVO) on the decision about the duration of secondary prophylaxis after a first venous thromboembolism (VTE). AIM: This study aimed at investigating the role of the mentioned VTE characteristics on the therapeutic decision using the information collected in the international, prospective, observational WHITE study. RESULTS: 1240 patients were recruited by 79 clinical centers in 7 countries (China, Czechia, Poland, Portugal, Russia, Slovakia, and Tunisia). 35 patients had as index event a pulmonary embolism (PE) without a deep vein thrombosis (DVT), and all continued anticoagulation. We focused on the 1205 subjects with DVT. The treatment decision differed among countries; altogether, more than 85% of patients with proximal (with or without distal) DVT continued a prophylactic treatment with anticoagulants, or antithrombotics; 34% of patients with isolated distal DVT stopped treatment, and more than 85% of patients with a PE associated to a DVT continued treatment. At multivariable analysis, the presence of proximal DVT, signs of post-thrombotic syndrome (PTS), residual vein obstruction (RVO), maintenance <180 days and concomitant diseases was associated with increased probability to continue secondary prophylaxis. CONCLUSION: The presentation as proximal DVT (with or without PE) or isolated PE influenced the treating physicians' decision in favor of extension of secondary prophylaxis, together with the presence of concomitant diseases and local conditions which may increase the risk of post-thrombotic syndrome.
650    _2
$a antikoagulancia $x terapeutické užití $7 D000925
650    _2
$a lidé $7 D006801
650    _2
$a prospektivní studie $7 D011446
650    12
$a plicní embolie $x komplikace $7 D011655
650    _2
$a rizikové faktory $7 D012307
650    12
$a žilní tromboembolie $x farmakoterapie $7 D054556
650    12
$a žilní trombóza $x komplikace $x farmakoterapie $7 D020246
655    _2
$a časopisecké články $7 D016428
655    _2
$a pozorovací studie $7 D064888
700    1_
$a Bignamini, Angelo A $u School of Specialization in Hospital Pharmacy, University of Milan, Italy
700    1_
$a Urbanek, Tomasz $u Medical University of Silesia, Katowice, Poland
700    1_
$a Cini, Michela $u Arianna Anticoagulazione Foundation, Bologna, Italy
700    1_
$a Li, Young-Jun $u Peking Union Medical College, Chinese Academy of Medical Sciences, Beijing, China
700    1_
$a Madaric, Juraj $u Clinic of Angiology, Comenius University and National Institute of Cardiovascular Diseases, Bratislava, Slovakia
700    1_
$a Bouslama, Kamel $u Faculty of Medicine of Tunis, Tunisia
700    1_
$a Sokurenko, German Y $u North-West Mechnikov State Medical University, St. Petersburg, Russia
700    1_
$a Andreozzi, Giuseppe M $u Angiology Unit, University of Padua, Italy
700    1_
$a Matuška, Jiří $u Clinical Trial Centre, Hodonin, Czechia
700    1_
$a Mansilha, Armando $u Faculty of Medicine, University of Porto, Portugal
700    1_
$a Barinov, Victor $u Central State Medical Academy of the Office of the President of the Russian Federation, Clinical hospital N. 1 "Volynskaya", Moscow, Russia
710    2_
$a WHITE study group
773    0_
$w MED00004518 $t Thrombosis research $x 1879-2472 $g Roč. 211, č. - (2022), s. 140-146
856    41
$u https://pubmed.ncbi.nlm.nih.gov/35151009 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220720 $b ABA008
991    __
$a 20220804135550 $b ABA008
999    __
$a ok $b bmc $g 1822792 $s 1170582
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2022 $b 211 $c - $d 140-146 $e 20220204 $i 1879-2472 $m Thrombosis research $n Thromb Res $x MED00004518
LZP    __
$a Pubmed-20220720

Najít záznam

Citační ukazatele

Pouze přihlášení uživatelé

Možnosti archivace